FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 419 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR How to Find Reliable and Affordable Transportation During Cancer January 23, 2024 Company Gives Cancer Patient a New HVAC System After Treatment and... March 8, 2019 ‘Dance Moms’ Star Abby Lee Miller Opens Up About Her Cancer... April 19, 2019 When Ovarian Cancer Returns, Surgery May Be a Good Choice for... January 12, 2022 Load more HOT NEWS Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma Workout Wednesdays – Leg Exercises Part 3 Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term... EMA Recommends Extension of Indications for Lorlatinib
